• Explore /
  • Poster
  • / Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.

Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.

Abstract Poster

Authors

Thierry Andre

Thierry Andre

Hôpital Saint-Antoine, Paris, France

Thierry Andre , Alfredo Falcone , Yaroslav V. Shparyk , Fedor Vladimirovich Moiseenko , Eduardo Polo , Tibor Csoszi , Arinilda Silva Campos Bragagnoli , Gabor Liposits , Ewa Chmielowska , Flore Delaporte , Hasnaa Hassan , Donia Skanji , Nadia Amellal , Mark P. Saunders

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03869892

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3512)

DOI

10.1200/JCO.2023.41.16_suppl.3512

Abstract #

3512

Poster Bd #

212

Abstract Disclosures

Similar Posters

First Author: Joyce O'Shaughnessy

First Author: Leisha A. Emens

First Author: David Cunningham

First Author: Clemens Albrecht Giessen